Investor Relations

Investor Relations

Company Profile

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Corcept has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a wide variety of serious disorders.


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations Contact Information

Phone: 650-327-3270